A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ACOUSTICS
- Sponsors Chugai Pharmaceutical; Roche
- 14 Nov 2022 Results of pooled analysis assessing the safety analysis of lebrikizumab during the 52-week placebo-controlled period of LAVOLTA I, LAVOLTA II, and ACOUSTICS studies, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
- 18 May 2022 According to Results presented at the 118th International Conference of the American Thoracic Society, the study was prematurely terminated (sponsors decision) potentially limiting interpretation of results.
- 18 May 2022 Status changed to discontinued, according to Results presented at the 118th International Conference of the American Thoracic Society